Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab.
PURPOSE To determine the incidence of poor responsiveness to VEGF-A suppression in eyes with diabetic macular edema (DME) by evaluating the effect of continuous delivery of ranibizumab via the Port Delivery Platform with ranibizumab (PDS) in individual patients enrolled in the Pagoda clinical trial. DESIGN Retrospect...